Abstract
Levomepromazine, an “older” typical neuroleptic, is widely applied in psychiatry for the treatment of schizophrenia. The biotransformation of Levomepromazine remains elusive up to now, but found to result in the formation of different derivatives that may contribute to the therapeutic and/or side-effects of the parent drug. The present work aims to resolve the metabolic details of Levomepromazine catalyzed by cytochrome P450, an important heme-containing enzyme superfamily, based on DFT calculation. Two main metabolic pathways have been addressed, S-oxidation and N-demethylation. The mechanistic conclusions have revealed a stepwise transfer of two electrons mechanism in S-oxidation reaction. N-demethylation is a two-step reaction, including the rate-determining N-methyl hydroxylation which proceeds via the single electron transfer (SET) mechanism and the subsequent C-N bond fission through a water-assisted enzymatic proton-transfer process. N-demethylation is more feasible than S-oxidation due to its lower activation energy and N-desmethyllevomepromazine therefore is the most plausible metabolite of Levomepromazine. Each metabolic pathway proceeds in a spin-selective manner (SSM) mechanism, predominately via the LS state of Cpd I. Our observations are in good accordance with the experimental results, which can provide some general implications for the metabolic mechanism of Levomepromazine-like drugs.
Similar content being viewed by others
References
Sivaraman P, Mitra A, Jayaram MB (2012) Levomepromazine for schizophrenia. Cochrane Database Syst Rev 38:219–220
Gjerden P, Slørdal L, Bramness JG (2010) Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur J Pharmacol 66:911–917
Green B, Pettit T, Faith L, Seaton K (2004) Focus on levomepromazine. Curr Med Res Opin 20:1877–1881
Dietz I, Schmitz A, Lampey I, Schulz C (2013) Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care 1:1
Bylund DB (1981) Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors. J Pharmacol Exp Ther 217:81–86
Hals PA, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: dopamine D2 receptor, α 1-and α 2-adrenoceptor binding. Eur J Pharmacol 125:373–381
Lal S, Thavundayil JX, Nair NV, Annable L (2006) Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. J Psychiatry Neurosci 31:271–279
Johnsen HELGE, Dahl SG (1982) Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Dispos 10:63–67
Hals PA, Dadl SG (1995) Metabolism of LM in man. Eur J Drug Metab Pharmacokinet 20:61–71
Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Prog Drug Metab 9:111–174
Dahl SG, Hjorth M, Hough E (1982) Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation. Mol Pharmacol 21:409–414
Dahl SG, Hall H (1981) Binding affinity of levomepromazine and two of its major metabolites to central dopamine and α-adrenergic receptors in the rat. Psychopharmacology 74:101–104
Wójcikowski J, Basińska A, Daniel WA (2014) The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application. Biochem Pharmacol 90:188–195
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA et al. (2013) Gaussian 09, revision D. 01. Gaussian, Inc, Wallingford
Blomberg MRA, Borowski T, Himo F, Liao RZ, Siegbahn PE (2014) Quantum chemical studies of mechanisms for metalloenzymes. Chem Rev 114:3601–3658
Shaik S, Cohen S, Wang Y, Chen H, Kumar D, Thiel W (2009) P450 enzymes: their structure, reactivity, and selectivity modeled by QM/MM calculations. Chem Rev 110:949–1017
Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091–38094
Chen Z, Kang Y, Zhang C, Tao J, Xue Y (2015) Metabolic mechanisms of caffeine catalyzed by cytochrome P450 isoenzyme 1A2: a theoretical study. Theor Chem Accounts 134:1–14
Tao J, Kang Y, Xue ZY, Wang YT, Zhang Y, Chen Q, Chen ZQ, Xue Y (2015) Theoretical study on the N-demethylation mechanism of theobromine catalyzed by P450 isoenzyme 1A2. J Mol Graph Model 61:123–132
Kwiecień RA, Molinié R, Paneth P, Silvestre V, Lebreton J, Robins RJ (2011) Elucidation of the mechanism of N-demethylation catalyzed by cytochrome P450 monooxygenase is facilitated by exploiting nitrogen-15 heavy isotope effects. Arch Biochem Biophys 510:35–41
Li D, Wang Y, Yang C, Han K (2009) Theoretical study of N-dealkylation of N-cyclopropyl-N -methylaniline catalyzed by cytochrome P450: insight into the origin of the regioselectivity. Dalton Trans 2:291–297
Wang Y, Wang HM, Wang YH, Yang CL, Yang L, Han KL (2006) Theoretical study of the mechanism of acetaldehyde hydroxylation by compound I of CYP2E1. J Phys Chem B 110:6154–6159
Kang Y, Tao J, Xue ZY, Zhang Y, Chen ZQ, Xue Y (2016) Quantum chemical exploration on the metabolic mechanisms of caffeine by flavin-containing monooxygenase. Tetrahedron 72:2858–2867
Xue ZY, Zhang Y, Tao J, Kang Y, Chen ZQ, Xue Y (2016) Theoretical elucidation of the metabolic mechanisms of phenothiazine neuroleptic chlorpromazine catalyzed by cytochrome P450 isoenzyme 1A2. Theor Chem Accounts 135:218. doi:10.1007/s00214-016-1943-4
Zhang Q, Bell R, Truong TN (1995) Ab initio and density functional theory studies of proton transfer reactions in multiple hydrogen bond systems. J Phys Chem 99:592–599
Reed AE, Schleyer PVR (1990) Chemical bonding in hypervalent molecules. The dominance of ionic bonding and negative hyperconjugation over d-orbital participation. J Am Chem Soc 112:1434–1445
Schröder D, Shaik S, Schwarz H (2000) Two-state reactivity as a new concept in organometallic chemistry. Acc Chem Res 33:139–145
Baciocchi E, Bietti M, Gerini MF, Lanzalunga O (2005) Electron-transfer mechanism in the N-demethylation of N, N-dimethylanilines by the phthalimide-N-oxyl radical. J Org Chem 70:5144–5149
Guengerich FP, Yun CH, Macdonald TL (1996) Evidence for a 1-electron oxidation mechanism in N-dealkylation of N, N-dialkylanilines by cytochrome p450 2b1 kinetic hydrogen isotope effects, linear free energy relationships, comparisons with horseradish peroxidase, and studies with oxygen surrogates. J Biol Chem 271:27321–27329
Jurva U, Bissel P, Isin EM, Igarashi K, Kuttab S, Castagnoli N (2005) Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines. J Am Chem Soc 127:12368–12377
Li C, Wu W, Kumar D, Shaik S (2006) Kinetic isotope effect is a sensitive probe of spin state reactivity in CH hydroxylation of N, N-dimethylaniline by cytochrome P450. J Am Chem Soc 128:394–395
Chen H, de Groot MJ, Vermeulen NP, Hanzlik RP (1997) Oxidative N-dealkylation of p-cyclopropyl-N, N-dimethylaniline. A substituent effect on a radical-clock reaction rationalized by ab initio calculations on radical cation intermediates. J Org Chem Rev 62:8227–8230
Acknowledgments
This work was supported by grants from National Natural Science Foundation of China (Grant No. 21203153), Science & Technology Department of Sichuan Province (Grant No. 2011JY0136) and Department of Education of Sichuan Province (Grant No. 12ZA174) and China West Normal University (Grant No. 11B002).
Author information
Authors and Affiliations
Corresponding author
Additional information
Yongting Wang and Qiu Chen contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 396 kb)
Rights and permissions
About this article
Cite this article
Wang, Y., Chen, Q., Xue, Z. et al. Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450. J Mol Model 22, 237 (2016). https://doi.org/10.1007/s00894-016-3107-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00894-016-3107-9